Antigen News and Research

RSS

Accurate, life-saving diagnostic tools needed for screening and prevention of prostate cancer, says AdMeTech

AdMeTech President and CEO Dr. Faina Shtern told the U.S. House Committee on Oversight and Government Reform that a major national commitment is needed to create accurate, life-saving diagnostic tools for prostate cancer and end what she called "the prostate cancer crisis."

4 Mar 2010

TNFerade's suppression of cancer metastases: Mechanisms revealed

GenVec, Inc. announced the publication of new preclinical research revealing mechanisms by which TNFerade(TM) suppresses cancer metastases through activation of the immune system.

4 Mar 2010

Abbott enters into agreement with GSK to develop molecular diagnostic test for skin cancer treatment

Abbott announced today that it has entered into an agreement with GlaxoSmithKline (GSK) to develop a molecular diagnostic test intended for use as an aid in selecting patients who may benefit from a skin cancer treatment in development by GSK.

4 Mar 2010

Researchers demonstrate the safety of potential vaccine against mesothelioma

Researchers have demonstrated the safety of a potential vaccine against mesothelioma, a rare cancer associated primarily with asbestos exposure. The vaccine, which infuses uses a patient's own dendritic cells (DC) with antigen from the patient's tumor, was able to induce a T-cell response against mesothelioma tumors.

4 Mar 2010

PCF: PSA screening remains valuable tool for identifying potential prostate disease

Responding to continued debate over PSA screening, and today’s American Cancer Society statement, the Prostate Cancer Foundation reiterated its position that PSA screening remains a valuable tool, in combination with other tools, for identifying potential prostate disease, including cancer.

4 Mar 2010

AUA Foundation joins AUA in response to the ACS updated prostate cancer screening guidelines

The American Urological Association Foundation joins the AUA in its response to the American Cancer Society updated prostate cancer screening guidelines highlighting the importance of shared decision-making between patients and physicians.

3 Mar 2010

Genetic Immunity to present data on DermaVir for HIV/AIDS at DNA Vaccines 2010

Genetic Immunity, a US/Hungarian biopharmaceutical company developing nanomedicine vaccines, will present data at this week’s DNA Vaccines 2010 in New Orleans, LA concerning the formulation and topical administration of the DermaVir therapeutic vaccine for HIV/AIDS. DNA Vaccine 2010 invites leading scientists to report on the latest research in the progressive field of DNA or Genetic Vaccines.

3 Mar 2010

Inovio Biomedical introduces new CELLECTRA-SP series of hand-held, cordless electroporation devices

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, has unveiled its new CELLECTRA®-SP series of hand-held, cordless electroporation devices at the DNA Vaccines 2010 conference being held in New Orleans, LA.

3 Mar 2010

Robotic surgery does not compromise clinical outcomes for prostate cancer surgery

Robotic surgical technology with its three-dimensional, high-definition view gives surgeons the sensation of touch, even as they operate from a remote console. A new study describes the phenomenon, called intersensory integration, and reports that surgical outcomes for prostate cancer surgery using minimally invasive robotic technology compare favorably with traditional invasive surgery.

3 Mar 2010

Enlarged prostate: Dutasteride-tamsulosin combination therapy more effective

Like any successful team effort, the best qualities of two drugs commonly prescribed for enlarged prostate yielded better results than either of the medicines alone, according to a new study from UT Southwestern Medical Center.

3 Mar 2010

ImmunoCellular Therapeutics receives Notice of Allowance on ICT-69 monoclonal antibody

ImmunoCellular Therapeutics, Ltd., a biotechnology company that is developing immune based therapies for the treatment of various forms of cancer, announced today it received a Notice of Allowance on monoclonal antibody ICT-69 which targets multiple myeloma and ovarian cancers. The antibody has demonstrated high specificity to these cancers by targeting a novel cell surface antigen.

2 Mar 2010

Intercell AG's revenues for full year 2009 increase 10.6%

Today, the biotech-vaccine company Intercell AG announced its financial results for Q4 and the preliminary results for the full financial year 2009, and presented an update on the Company's development programs.

2 Mar 2010

AdMeTech Foundation: Health care reform highlights need for better screening and prevention of prostate cancer

AdMeTech Foundation announced today that its President and CEO Dr. Faina Shtern will testify on March 4 before the U.S. House Committee on Oversight and Government Reform on how health care reform highlights the need for increased funding for research aimed at creating accurate, life-saving diagnostic tools for prostate cancer, which will improve screening, prevention, early detection and reduce health costs.

2 Mar 2010

arGEN-X SIMPLE Antibody platform delivers multiple, diverse, ultra-potent functional antibodies

SIMPLE Antibody(TM) Platform Delivers Unprecedented Choice of Ultra-Potent Functional Antibody Leads Against Challenging Soluble and Cell Surface Targets. - ARGX-109, a Fully Human mAb Targeting Autoimmune, Inflammation and Oncology Indications, Enters Preclinical Development in Less Than 12 Months From Start of Discovery.

1 Mar 2010

α-defensins1-3 may be potential prophylactic agents in treatment of HIV / AIDS

HIV/AIDS remains one of the world's most significant public health challenges, particularly in developing countries. The Human Immunodeficiency Virus (HIV-1), the variant responsible for the pandemic, has the ability to infect different cell types such as T cells, macrophages and dendritic cells (DC). These latter cells are crucial in the defense against infectious agents and play a major role in viral pathogenesis.

25 Feb 2010

PharmAthene awarded total of $78.4M in additional funding to develop SparVax vaccine

PharmAthene, Inc. a biodefense company specializing in the development and commercialization of medical countermeasures against chemical and biological threats, announced today that the Department of Health and Human Services, through the Biomedical Advanced Research and Development Authority has modified its existing research and development contract with PharmAthene providing for up to a total of $78.4 million in additional funding, provided that certain milestones are achieved and that all contract options and extensions are exercised by the government, to support the continued advanced development of SparVax™, a second generation recombinant protective antigen (rPA) anthrax vaccine targeted for future procurement in the U.S. Strategic National Stockpile.

24 Feb 2010

Nitric oxide may play key role in the pathogenesis of neonatal meningitis

Current research suggests that nitric oxide may play a role in the pathogenesis of neonatal meningitis. The related report by Mittal et al, "Inhibition of inducible nitric oxide controls pathogen load and brain damage by enhancing phagocytosis of Escherichia coli K1 in neonatal meningitis," appears in the March 2010 issue of The American Journal of Pathology.

24 Feb 2010

Genocea Biosciences secures licensing to extensive HSV antigen patent estate

Genocea Biosciences, a leading vaccine discovery and development company, today announced that it has licensed an extensive patent estate from the University of Washington and the Fred Hutchinson Cancer Research Center for 25 pending and issued patents related to herpes simplex virus (HSV) type 2 antigens. The addition of these patents complements the novel antigens discovered by Genocea’s unique and proprietary antigen discovery technology. The combination of Genocea’s novel intellectual property with the patent estate from the University of Washington provides the Company with a broad compendium of HSV antigen patents.

24 Feb 2010

GlycoVaxyn initiates Phase I clinical study of GVXN SD133 vaccine candidate against Shigella dysenteriae

GlycoVaxyn, a pioneer in the development of innovative bioconjugate vaccines, has commenced a Phase I clinical study with its vaccine candidate (GVXN SD133) against Shigella dysenteriae, a cause of serious intestinal infections. This is the first product from the company to enter clinical evaluation.

23 Feb 2010

Study shows CEL-2000 vaccine blocks RA progression in mice

CEL-SCI Corporation and their scientific collaborators announced today that the Company's CEL-2000 vaccine demonstrated that it is able to block the progression of rheumatoid arthritis (RA) in a mouse model.

23 Feb 2010

Antigen News and Research

Accurate, life-saving diagnostic tools needed for screening and prevention of prostate cancer, says AdMeTech

TNFerade's suppression of cancer metastases: Mechanisms revealed

Abbott enters into agreement with GSK to develop molecular diagnostic test for skin cancer treatment

Researchers demonstrate the safety of potential vaccine against mesothelioma

PCF: PSA screening remains valuable tool for identifying potential prostate disease

AUA Foundation joins AUA in response to the ACS updated prostate cancer screening guidelines

Genetic Immunity to present data on DermaVir for HIV/AIDS at DNA Vaccines 2010

Inovio Biomedical introduces new CELLECTRA-SP series of hand-held, cordless electroporation devices

Robotic surgery does not compromise clinical outcomes for prostate cancer surgery

Enlarged prostate: Dutasteride-tamsulosin combination therapy more effective

ImmunoCellular Therapeutics receives Notice of Allowance on ICT-69 monoclonal antibody

Intercell AG's revenues for full year 2009 increase 10.6%

AdMeTech Foundation: Health care reform highlights need for better screening and prevention of prostate cancer

arGEN-X SIMPLE Antibody platform delivers multiple, diverse, ultra-potent functional antibodies

α-defensins1-3 may be potential prophylactic agents in treatment of HIV / AIDS

PharmAthene awarded total of $78.4M in additional funding to develop SparVax vaccine

Nitric oxide may play key role in the pathogenesis of neonatal meningitis

Genocea Biosciences secures licensing to extensive HSV antigen patent estate

GlycoVaxyn initiates Phase I clinical study of GVXN SD133 vaccine candidate against Shigella dysenteriae

Study shows CEL-2000 vaccine blocks RA progression in mice

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics